More recently, it was reported that Transient Receptor Potential Melastatin 3 (TRPM3) activity was lost in CFIDS patients, and there was no significant difference in TRPM3 ion channel activity between CFIDS patients and post-COVID-19 patients [88]. This evidence concerns the gene TRPM3 and COVID-19.